MannKind licenses Afrezza to Sanofi

MannKind Corp. (NASDAQ:MNKD) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize Afrezza inhaled insulin to treat adults with Type I and II diabetes.

Read the full 260 word article

User Sign In